Month: June 2026

Introduction and Objective: Faricimab, the only bispecific antibody targeting both Ang-2 and VEGF-A, is a novel treatment for diabetic macular edema (DME). Real-world evidence is lacking on the impact of baseline diabetes severity on its long-term clinical/economic outcomes.Methods: This retrospective cohort study linked a DME cohort from a large national payer (administrative claims) with the […]

Introduction and Objective: Implementing lifestyle interventions guided by continuous glucose monitor (CGM) data can potentially prevent progression and reduce risk of prediabetes and type 2 diabetes (T2D). Maintaining healthy behaviors is particularly difficult in high-stress work environments like health care workers (HCWs). Sutter Health created a Metabolic Wellness Program (MWP) to educate on interpreting CGM […]

Introduction and Objective: Use of continuous glucose monitoring (CGM) and glucose biosensors are increasing in people without diabetes to support health and wellness. However, there is currently limited data on the CGM profile of older adults without diabetes. This study examined the CGM profile of older men without diabetes over 24 hours.Methods: Thirty-three older men […]

Introduction and Objective: Impaired function of large-conductance Ca²+-activated K+ (BK) channels is associated with coronary artery dysfunction in diabetes mellitus. We previously reported that BK channel function is regulated by Src homology 3 (SH3) domain-containing protein 2 (Sorbs2) and its upstream regulator, nuclear factor erythroid 2-related factor 2 (Nrf2), in the coronary arterial smooth muscle […]

Introduction and Objective: Older adults with obesity are at increased risk for metabolic dysfunction and type 2 diabetes. Aging and excess adiposity promote the accumulation of senescent cells in adipose tissue (AT), contributing to chronic inflammation and impaired adipocyte function. Lifestyle interventions including weight loss and exercise improve metabolic health in older adults with obesity; […]

Introduction and Objective: Antidiabetic agents differ in their mechanisms of action and can exert distinct long-term effects on β-cell function (BCF). Hyperglycemic clamp studies (HC) enable detailed assessment of first- and second-phase insulin secretion (ISecr), yet comparative longitudinal data across drug classes among individuals with PreDM remains limited.Methods: Sixty PreDM subjects were studied and treated […]

Introduction and Objective: To evaluate the feasibility and effectiveness of the PACTAID application in reducing hypoglycemia during and after exercise in adults with type 1 diabetes (T1D) using the Tandem Control-IQ system.Methods: In this prospective study, adults with T1D on Control-IQ completed 20 exercise sessions with PACTAID support. Baseline and end-of-study assessments included ambulatory blood […]

Introduction and Objective: Food insecurity is a key risk factor for severe hypoglycemia among insulin users. Whether this extends to non-insulin-treated secretagogue users remains unexamined, despite widespread prescribing of these agents, particularly in cost-sensitive contexts. We analyzed data from the iNPHORM study to address this gap.Methods: Adults (≥18 years) with type 2 diabetes (T2D) on […]

Introduction and Objective: Diabetic ketoacidosis (DKA) and severe hypoglycemia (SH) require costly, high-intensity acute care. Recent trends in type 2 diabetes (T2D) are not well described. We estimated annual prevalence of DKA and SH requiring emergency department (ED) or inpatient (IP) care among people with T2D.Methods: We analyzed Inovalon Insights claims (2017-2024) from Commercial, Managed […]

Introduction and Objective: GLP-1 RAs and SGLT-2i have transformed T2DM management by improving glycemic control, promoting weight loss, and reducing the risk of cardiometabolic-renal disease. This study’s aim was to assess real world prescribing patterns of GLP-1 RAs and SGLT-2i within a large health care system and assess variations across sociodemographic groups.Methods: A retrospective analysis […]